IAIM
LCTX icon

International Assets Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

International Assets Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4 Hold
3
– – ﹤0.01% 2350
2026
Q1 		$5 Hold
3
– – ﹤0.01% 2245
2025
Q4 		$5 Buy
+3
New +$5 ﹤0.01% 2200

Other funds holding LCTX

DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RCWM
Red Crane Wealth Management San Francisco, California $136M AUM 18.56% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
BWCS
Beirne Wealth Consulting Services Shelton, Connecticut $503M AUM 27.98% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

International Assets Investment Management's LCTX Position: Q2 2026 in Review

International Assets Investment Management held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 3 shares worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #2350.

International Assets Investment Management first reported a position in LCTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $5 in Q1 2026. 32 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • International Assets Investment Management held 3 shares of Lineage Cell Therapeutics worth $4 as of Q2 2026.
  • International Assets Investment Management left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of International Assets Investment Management's portfolio in Q2 2026, its #2350 holding.
  • International Assets Investment Management first reported a position in Lineage Cell Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • International Assets Investment Management's Lineage Cell Therapeutics position peaked at $5 in Q1 2026.
  • 32 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on International Assets Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.